Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Tue, 04.04.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023 Ladenburg, Germany, 4th April 2023 – Heidelberg Pharma AG (FSE: HPHA) will present data from preclinical studies at this year's American Association for Cancer Research (AACR) annual meeting that provide positive [ … ]
Technical analysis
To the publication
Tue, 04.04.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023 Ladenburg, Germany, 4th April 2023 – Heidelberg Pharma AG (FSE: HPHA) will present data from preclinical studies at this year's American Association for Cancer Research (AACR) annual meeting that provide positive [ … ]
Technical analysis
To the publication
Fri, 24.03.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business Start of clinical trial and first safety data with HDP-101 in multiple myeloma Conclusion and implementation of a strategic partnership with Huadong Medicine Successful financing activities Financials in line with adjusted guidance  [ … ]
Technical analysis
To the publication
Fri, 24.03.2023       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business Start of clinical trial and first safety data with HDP-101 in multiple myeloma Conclusion and implementation of a strategic partnership with Huadong Medicine Successful financing activities Financials in line with adjusted guidance  [ … ]
Technical analysis
To the publication
Fri, 16.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of [ … ]
Technical analysis
To the publication
Fri, 16.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta [ … ]
Technical analysis
To the publication
Thu, 10.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 Heidelberg Pharma presents initial findings of the first in human study with ATAC® candidate HDP-101 Licensing partner Magenta presents initial data from Phase I/II study with ATAC® candidate MGTA- [ … ]
Technical analysis
To the publication
Thu, 10.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 Heidelberg Pharma presents initial findings of the first in human study with ATAC® candidate HDP-101 Licensing partner Magenta presents initial data from Phase I/II study with ATAC® candidate MGTA- [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.